Jaikumar Ramamoorthy

Dr. Jaikumar Ramamoorthy

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
VRVenkatraman Radhakrishnan
Venkatraman Radhakrishnan
AJArchit Joshi
Archit Joshi
JRJaikumar Ramamoorthy
Jaikumar Ramamoorthy
SRSwaminathan Rajaraman
Swaminathan Rajaraman
PGPrasanth Ganesan
Prasanth Ganesan
TSTenali G. Sagar
Tenali G. Sagar

3 January 2022 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
EREmine A. Rahiman
Emine A. Rahiman
SBSameer Bakhshi
Sameer Bakhshi
DPDeepam Pushpam
Deepam Pushpam
JRJaikumar Ramamoorthy
Jaikumar Ramamoorthy
ADAnirban Das
Anirban Das
ATAmita Trehan
Amita Trehan
The literature on B-non-Hodgkin lymphoma (NHL) in India is restricted to individual hospital data. The study aimed to evaluate the epidemiology and outcome of B-NHL in our country. One hundred and ninety-one patients of B-NHL from 10 centers diagnosed between 2013 and 2016 were analyzed retrospectively. B/T lymphoblastic lymphoma and patients with inadequate data were excluded. The median age was 88 months (IQR: 56, 144) with an M:F ratio of 5.6:1. Undernourishment and stunting were seen in 36.5% and 22%. Primary site was abdomen in 66.5%. Hypoalbuminemia was noted in 82/170 (48.2%). Histological subtypes: Burkitt lymphoma (BL): 69.6%, Burkitt-like: 10.4%, and diffuse large B cell lymphoma (DLBCL): 13.6%, unclassified and others (6.4%). Stage distribution: I/II, 33 (17.3%), III, 114 (59.7%), and IV, 44 (23%). One-eighty-six patients took treatment. Protocols used were LMB and BFM in 160/186 (86%). At a median follow-up of 21.34 (IQR: 4.34, 36.57) months, the disease-free-survival (DFS) was 74.4% and event-free-survival (EFS) was 60.7%. Treatment-related mortality (TRM), relapse/progression and abandonment were 14.3%, 14.5%, and 8.4%, respectively. Bone marrow positivity, stage IV disease, and lactate dehydrogenase (LDH) > 2,000 U/l predicted inferior EFS. Stage IV disease, LDH > 2,000 U/l, bone marrow positivity, tumor lysis syndrome and low albumin predicted TRM; LDH retained significance on multivariate analysis for EFS and TRM [OR: 4.54, 95% CI: 1.14–20, p 0.03; OR 20, 95%CI: 1.69–250, p 0.017]. BL was the main histological subtype. High TRM and relapse/progression are hampering survival. An LDH > 2,000 U/l was adversely prognostic. These data demonstrate a need to develop a national protocol that balances toxicity and potential for cure.

2 January 2023 in Indian Pediatrics
Verified
Journal Article
Closed access
PDF file
ACAakash Chandran Chidambaram
Aakash Chandran Chidambaram
JRJaikumar Ramamoorthy
Jaikumar Ramamoorthy
AAAvinash Anantharaj
Avinash Anantharaj

23 July 2022 in Journal of Paediatrics and Child Health
Verified
Journal Article
Closed access
PKPediredla Karunakar
Pediredla Karunakar
JRJaikumar Ramamoorthy
Jaikumar Ramamoorthy
AAAvinash Anantharaj
Avinash Anantharaj
NPNarayanan Parameswaran
Narayanan Parameswaran
NBNiranjan Biswal
Niranjan Biswal
AGAnitha Gunalan
Anitha Gunalan

29 December 2022 in Indian Pediatrics
Verified
Journal Article
Closed access
PDF file
GSGulrej Nisar Shaikh
Gulrej Nisar Shaikh
JRJaikumar Ramamoorthy
Jaikumar Ramamoorthy
NPNarayanan Parameswaran
Narayanan Parameswaran
GSGandhipuram Periyasamy Senthilkumar
Gandhipuram Periyasamy Senthilkumar

23 September 2023 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
VRVenkatraman Radhakrishnan
Venkatraman Radhakrishnan
VKVenkatakrishnan Kritthivasan
Venkatakrishnan Kritthivasan
BKBalaji Thiruvengadam Kothandan
Balaji Thiruvengadam Kothandan
PSPrasanth Srinivasan
Prasanth Srinivasan
GDGargi Das
Gargi Das
JRJaikumar Ramamoorthy
Jaikumar Ramamoorthy